+ 0.89
+ 0.26%
+ 0.07
+ 0.02%
+ 0.75
+ 0.18%

Compass Pathways Reports Positive Results From Psilocybin Study

December 16, 2019 1:40 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Compass Pathways Reports Positive Results From Psilocybin Study

The mental health care company COMPASS Pathways reported Thursday that its its COMP350 (psilocybin) was well-tolerated by healthy volunteers who participated in a placebo-controlled trial at King’s College London.

The active ingredient in magic mushrooms provoked no serious adverse events, according to the study. 

Most of the adverse events were anticipated and included changes in sensory perception and positive mood transformations, the company said. 

The study concluded that “COMP360 had no negative effects on cognitive and emotional functioning.”

Don’t miss out on the top cannabis stories of the day. Click here to sign up for our daily insider newsletter.

The study examined the effects of 10mg and 25mg doses of COMP360 versus a placebo in 89 healthy volunteers.

"This is the largest controlled study of psilocybin to date. The results of the study are clinically reassuring and support further development of psilocybin as a treatment for patients with mental health problems that haven't improved with conventional therapy, such as treatment resistant depression," Dr. James Rucker, the lead investigator of the study, said in a statement.

Related Links:

The Keys To Understanding Psilocybin's Medical Value, Market Potential

California Activists Fight To Decriminalize Psilocybin Mushrooms

Photo by Alan Rockefeller via Wikimedia

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.

Related Articles

Red Light Holland Buys Virtual Reality Company And Majority Stake In Grow-At-Home Mushroom Company

Red Light Holland Corp. (Canadian: TRIP) (OTC Pink: TRUFF), a company looking at recreational markets in the psychedelics space, closed two major acquisitions this week. read more

Cybin To Co-Sponsor Clinical Trial Testing Psilocybin In Frontline Health Workers With Covid-related Distress

Psychedelics and biotech company Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) is co-sponsoring a new clinical trial that will test the benefits of psilocybin treatment in health workers experiencing COVID-related distress. read more

Marijuana Etiquette: It's A Real Thing And A New Book Breaks It Down

This past Tuesday, cannabis industry reporter and Benzinga author Andrew Ward celebrated the release of his second book, “The Art of Marijuana Etiquette: A Sophisticated Guide to the High Life.” read more

Peter Thiel-Backed Psychedelic Firm Atai Sets Terms For US IPO, Sees $2.3B Valuation

Atai Life Sciences B.V., backed by billionaire investor Peter Thiel, has announced terms for its initial public offering.  read more